Plain language summary of the ASCENT Study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

This Plain Language Summary of publication article (PLSP) from Future Oncology covers the ASCENT study on Sacituzumab Govitecan (TRODELVY®), a treatment for metastatic triple-negative breast cancer (mTNBC). The study compared Sacituzumab Govitecan to standard chemotherapy in 529 patients with mTNBC across seven countries. Results showed patients treated with Sacituzumab Govitecan lived longer and had more tumor shrinkage, though they experienced more side effects like neutropenia and diarrhea. Supportive care helped manage these side effects.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.

• antibody–drug conjugate
• breast cancer
• lay summary
• plain language summary
• sacituzumab govitecan
• triple-negative breast cancer
• Trop-2